By Fineline Cube 
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its Venclexta (venetoclax), a first-in-class BCL-2 inhibitor co-developed by Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY). The drug is approved for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) harboring the 17p deletion mutation, who have received at least one prior therapy. This approval makes Venclexta the first of its kind globally as a targeted CLL treatment.
Global Commercialization
Venclexta is jointly commercialized by AbbVie and Genentech (a member of the Roche Group) in the US. Outside the US, AbbVie is solely responsible for commercialization. The drug has been approved in over 80 countries/regions worldwide, including the US. It is the subject of clinical studies in multiple hematological malignancies.-Fineline Info & Tech